Clinical Trials
3 trialsNCT07567352 2026-05-12
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
Active not recruiting
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT07083687 2025-07-24
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Hunan Cancer Hospital
Phase 2 Not yet recruiting